Literature DB >> 11257031

DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening.

D Sereno1, G Roy, J L Lemesre, B Papadopoulou, M Ouellette.   

Abstract

Protocols for DNA electroporation in Leishmania promastigote cells are well established. More recently, in vitro culture of axenic Leishmania amastigotes became possible. We have established conditions for DNA transformation of axenically grown Leishmania infantum amastigotes. Parameters for DNA electroporation of Leishmania axenic amastigotes were systematically studied using luciferase-mediated transient transfection. Cell lines expressing stable luciferase activity were then selected, and their ability to be used in an in vitro drug screening procedure was determined. A model was established, using axenic amastigotes expressing luciferase activity, for rapidly determining the activity of drugs directly against both axenic and intracellular amastigotes. For intracellular amastigotes, the 50% effective concentrations of pentamidine, sodium stibogluconate (Pentostam), meglumine (Glucantime), and potassium antimonyl tartrate determined with the luciferase assay were 0.2 microM (0.12 microg/ml), 55 microg/ml, 95 microg/ml, and 0.12 microg/ml, respectively; these values are in agreement with values determined by more labor-intensive staining methods. We also showed the usefulness of luciferase-expressing parasites for analyzing drug resistance. The availability of luciferase-expressing amastigotes for use in high-throughput screening should facilitate the search for new antileishmanial drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257031      PMCID: PMC90440          DOI: 10.1128/AAC.45.4.1168-1173.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Increased transport of pteridines compensates for mutations in the high affinity folate transporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae.

Authors:  C Kündig; A Haimeur; D Légaré; B Papadopoulou; M Ouellette
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

3.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Leishmania mexicana: drug sensitivities of promastigotes and transforming amastigotes.

Authors:  G H Coombs; D T Hart; J Capaldo
Journal:  J Antimicrob Chemother       Date:  1983-02       Impact factor: 5.790

6.  ABC transporters in Leishmania and their role in drug resistance.

Authors:  M Ouellette; D Légaré; A Haimeur; K Grondin; G Roy; C Brochu; B Papadopoulou
Journal:  Drug Resist Updat       Date:  1998-03       Impact factor: 18.500

7.  Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis.

Authors:  L A Collins; M N Torrero; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 8.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

9.  Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages.

Authors:  J D Berman; L S Lee
Journal:  J Parasitol       Date:  1984-04       Impact factor: 1.276

10.  Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.

Authors:  M Ephros; A Bitnun; P Shaked; E Waldman; D Zilberstein
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  40 in total

1.  Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.

Authors:  Suman Gupta; Shyam Sundar; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  A Telomeric Cluster of Antimony Resistance Genes on Chromosome 34 of Leishmania infantum.

Authors:  Paloma Tejera Nevado; Eugenia Bifeld; Katharina Höhn; Joachim Clos
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.

Authors:  D Sereno; P Holzmuller; I Mangot; G Cuny; A Ouaissi; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies.

Authors:  Ricardo Silvestre; Anabela Cordeiro-da-Silva; Joana Tavares; Denis Sereno; Ali Ouaissi
Journal:  Immunology       Date:  2006-10-09       Impact factor: 7.397

5.  Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Authors:  Barbara Papadopoulou; Gaétan Roy; Marie Breton; Christoph Kündig; Carole Dumas; Isabelle Fillion; Ajay K Singh; Martin Olivier; Marc Ouellette
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Identification of new leishmanicidal peptide lead structures by automated real-time monitoring of changes in intracellular ATP.

Authors:  J Román Luque-Ortega; José M Saugar; Cristina Chiva; David Andreu; Luis Rivas
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

7.  An experimental approach for the identification of conserved secreted proteins in trypanosomatids.

Authors:  Rosa M Corrales; Françoise Mathieu-Daudé; Déborah Garcia; Simone F Brenière; Denis Sereno
Journal:  J Biomed Biotechnol       Date:  2010-01-17

8.  Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes.

Authors:  Adriano C Coelho; Nadine Messier; Marc Ouellette; Paulo C Cotrim
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

9.  Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites.

Authors:  Christian Brochu; Jingyu Wang; Gaétan Roy; Nadine Messier; Xiao-Yan Wang; Nancy G Saravia; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Modulation of gene expression in human macrophages treated with the anti-leishmania pentavalent antimonial drug sodium stibogluconate.

Authors:  Karima El Fadili; Michaël Imbeault; Nadine Messier; Gaétan Roy; Benjamin Gourbal; Marc Bergeron; Michel J Tremblay; Danielle Légaré; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.